• Guardio

  Participated · Equity · Nov 2025

  Founded in 2018, Guardio began as a browser extension that scans for malicious or phishing sites and alerts users to data leaks. The company has since expanded into mobile applications providing identity management, spam filtering, and scam protection, and it is now developing technology to detect malicious code written with AI-based “vibe coding” tools. Guardio is also rolling out visibility features that reveal publicly shared documents, flag sensitive information exposure, and identify accounts lacking multi-factor authentication, with planned Outlook and Facebook integrations and a free-tier rollout next year. The startup recently partnered with website builder Lovable to scan every site on that platform for security flaws. Guardio reports 500,000 paying users and says it reached $100 million in annual recurring revenue in 2024. Management states that, although its valuation has tripled since 2021, the company does not yet consider itself a unicorn.

• XTEND

  Participated · Series B · Jul 2025

  Founded in 2018 by Aviv Shapira, Matteo Shapira, Rubi Liani and Adir Tubi, XTEND builds next-generation autonomous platforms that allow operators to remotely control aerial, ground and maritime drones through its proprietary XOS operating system. The technology is designed to keep personnel out of harm’s way while executing complex, dynamic tasks for defense, public safety and private security customers. XTEND’s field-proven systems are already deployed and the company plans to scale NDAA-compliant domestic manufacturing at its Tampa, Florida facility. Proceeds from its latest transaction will fund accelerated delivery to customers in the United States, NATO member states and Asia. XTEND operates in Israel, the United States and Singapore and will rebrand as XTEND AI Robotics when it lists on Nasdaq. The forthcoming public listing values the company at $1.5 billion. Roughly six months before this deal, XTEND closed a $70 million round jointly led by Protego Ventures and Aliya Capital.

• Eleos Health

  Participated · Series C · Jan 2025

  Eleos builds AI agents and multimodal LLM-powered tools that streamline clinical documentation, surface care insights, and improve patient engagement for behavioral health providers. The company recently launched Eleos Compliance, a clinical documentation improvement (CDI) product that uses agentic AI to flag documentation errors and simplify appeals and accreditation work. Eleos uses the industry’s largest dataset of real-world treatment sessions and claims randomized controlled trial results showing >80% faster progress note submission, doubled client engagement, and 3–4x improved care outcomes versus treatment as usual. The company has more than 120 customer organizations across 30+ U.S. states and reports rapid revenue growth, tripling annual revenue over its first three years and doubling revenue in 2024. Eleos plans to use new funding to expand product offerings, grow its commercial team, hire senior leaders and engineering/data talent, and push into underserved segments—particularly substance use disorder and post-acute behavioral healthcare. Eleos Health develops AI that interprets, analyzes and documents behavioral health conversations using proprietary, behavioral health–specific large language models trained on treatment data and clinical expertise. The system reduces operational burden on providers by automating documentation and surfacing objective insights into evidence-based care and the therapeutic alliance. Leadership teams can scale supervision and training and gain visibility into staff activity, caseloads, performance and population health. The company plans new and enhanced AI solutions for group therapy, compliance automation, case management, concurrent documentation and value‑based care support. Eleos intends to expand its reach to more behavioral health providers and segments, deepen strategic partnerships with EHRs and industry associations, and hire more than 50 people by the end of 2024. It is led by CEO Alon Joffe and is based in Boston and Tel Aviv. Eleos Health provides CareOps Automation solutions that consolidate the behavioral care workflow by automating operational necessities, including documentation and compliance administration, and by delivering session intelligence. Its session intelligence tools generate clinical insights that enable clinicians, providers, and networks to track treatment and progress in a measurable way. The company is led by CEO Alon Joffe and is used by thousands of clinicians across more than 20 national care providers and health plans, including Gaudenzia Home, The Brookline Center for Mental Health, and Coleman Health Services. Eleos has captured more than 6.5 million minutes of treatment to date and is projecting 30 million minutes captured by the end of 2022. The company intends to use the funding to accelerate growth and expand its operations, team, and product. Eleos is based in Boston, MA. Eleos Health develops an AI-powered Speech-to-Insights system that analyzes behavioral health sessions to surface actionable insights for clinicians. Its VoiceAI technology runs securely in the background of sessions and analyzes hundreds of data parameters to accelerate clinical decision-making and personalize care. The company has deployed its solution with over a dozen provider organizations, including Solvista Health, Achieve, Yeshiva University and ReachLink. Eleos plans to use the recent funding to expand sales, marketing, and solution delivery teams needed to meet demand for enterprise software deployments across providers and payors. Founded in 2020 and based in Boston and Tel Aviv, the company has added Dr. David Shulkin to its board. Eleos closed a $6M seed round in 2021.

• Addionics

  Participated · Series A · Jan 2022

  Addionics produces textured, three-dimensional copper and aluminum foil current collectors for lithium-ion batteries, using electro-deposition for copper and electroetching for aluminum. Its foils feature tiny holes and undulating peaks and valleys that increase contact between the foil and active material. The company says the design improves battery performance and efficiency and can potentially double battery lifespan, and that the collectors can work with a wide range of chemistries. Addionics plans to tailor collectors to different chemistries in the future to extract additional performance. The Israel- and U.K.-based startup recently raised a $39 million Series B to accelerate delivery of its current collectors and to explore new markets and geographies. Earlier this year it announced plans to build a $400 million factory in the U.S. and said it has letters of intent from U.S. automakers. Addionics develops patented Smart 3D Electrode architecture and a scalable electrode fabrication process that replaces traditional 2D layered electrodes, aiming to increase energy density, power, safety and lifetime without raising cost. Its drop-in solution is compatible with existing battery manufacturing lines and is paired with a proprietary AI algorithm to accelerate and optimize electrode design for varied applications. The company targets electric vehicles initially and is collaborating with automotive OEMs and suppliers in the U.S. and Europe to integrate with NMC, LFP, silicon, lithium polymer and solid-state chemistries. Addionics plans to commercialize by 2024 and will use funding to advance product development, expand the team, and increase activity in the U.S. and Germany. The company also highlights applications beyond EVs, including consumer electronics, stationary storage, aviation, defense and medical devices. Addionics has developed a scalable, patent‑protected “smart 3D structure” that redesigns battery architecture via 3D metal fabrication to reduce internal resistance and improve mechanical longevity and thermal stability. The company’s approach is chemistry‑agnostic, designed to enhance existing and future battery chemistries rather than replace them. Addionics says its technology can increase EV mileage, improve safety, and reduce cost and charging time, and could be applied to consumer electronics, medical devices, grid storage, drones, and more. Commercial traction is early: the company is working with an unnamed tier‑1 American automotive company on a proof‑of‑concept and testing Addionics cells in vehicles. Management aims to secure 3–4 major collaborations with world‑leading OEMs over the next year. Financially, the company has raised $6M in funding, which includes a $2.5M grant awarded through the European Union’s Horizon2020 program.

• MeMed

  Participated · Equity · Jan 2022

  MeMed develops rapid host immune-response diagnostic tests that decode the body’s immune signals to help clinicians distinguish bacterial from viral infections and predict COVID-19 severity. The company’s MeMed BV® test received FDA clearance for use on the point-of-need MeMed Key® platform to aid in distinguishing bacterial and viral infections in children and adults. MeMed also markets the MeMed COVID-19 Severity™ test, which has been cleared for use in Europe. The company says it will use new funding to scale manufacturing, accelerate commercialization and expand its host-response product portfolio, with a particular operational focus on the U.S. MeMed reports total funding now exceeds $200 million, including prior support from the U.S. Department of Defense and the EU Commission. The company maintains a presence in Haifa, Israel and Boston, MA. MeMed has developed and validated an immune-based protein signature called MeMed BV™ to distinguish between bacterial and viral infections. The company is also completing development of MeMed Key™, a point-of-care protein measurement platform, and plans to upscale manufacturing and seek clearance for that device. MeMed intends to expand its pipeline of tests that integrate machine learning with immune-based measurements to address major clinical challenges. The company is led by co‑founders Dr. Eran Eden (CEO) and Dr. Kfir Oved (CTO). MeMed completed an over $70M financing round to support market adoption, product development, manufacturing scale-up, regulatory clearance efforts, and pipeline expansion. MeMed develops host-response diagnostics built on its ImmunoXpert platform, which measures a three-protein signature (TRAIL, IP-10 and C-reactive protein) to differentiate bacterial and viral infections. The technology has been validated in large studies but cannot identify exact pathogen strains. The current instrument requires about two hours and a trained technician, limiting emergency-room use. Co-founders CEO Eran Eden and CTO Kfir Oved are developing a second-generation benchtop device that would use the same three proteins and algorithm to deliver results in under 15 minutes from a drop of blood and be plug-and-play. MeMed's stated clinical goal is to right-size antibiotic use to reduce inappropriate prescriptions and slow antibiotic resistance. The company received DTRA funding to accelerate development of the faster, easier-to-use instrument.

No current team members are available.